Omentin-1 vs hGHRH(1-40)OH
Head-to-head comparison of Omentin-1 (Omentin-1 (Intelectin-1, ITLN1)) and hGHRH(1-40)OH (Human growth hormone-releasing factor (1-40) hydroxyl) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Omentin-1 | hGHRH(1-40)OH |
|---|---|---|
| Category | Diabetes & Metabolic | Growth Hormone |
| Full Name | Omentin-1 (Intelectin-1, ITLN1) | Human growth hormone-releasing factor (1-40) hydroxyl |
| Molecular Weight | ~35 kDa | N/A |
| Half-Life | hours | 5-20 minutes |
| Amino Acids | 313 | 40 |
| Typical Dose | No approved human dose; research use only | 1-2 mcg/kg |
| Route | IV|SC | Subcutaneous/IV |
| Purity | ≥98% | ≥98% |
| Studies Count | 82 | 85 |
| Research Status | Pre-clinical | Clinical Research |
Omentin-1 Benefits
- ✓insulin sensitivity
- ✓glucose uptake
- ✓lipid handling
hGHRH(1-40)OH Benefits
- ✓GH secretion research
- ✓fragment-activity comparison
- ✓receptor binding studies
- ✓axis physiology modeling
Omentin-1 Dosing
not established|not established
hGHRH(1-40)OH Dosing
1-2 mcg/kg SC or IV in acute research settings|single-bolus GH stimulation protocols|repeated low-dose administration in comparative studies
Omentin-1 Side Effects
- ⚠unknown
- ⚠immunogenicity risk
hGHRH(1-40)OH Side Effects
- ⚠flushing
- ⚠headache
- ⚠lightheadedness
Research Overview
Omentin-1
Lower omentin-1 levels are often associated with obesity, insulin resistance, and metabolic syndrome. Research continues on its use as a biomarker and as a mechanistic lead for AMPK-linked metabolic interventions.
hGHRH(1-40)OH
Human GHRF(1-40)OH has been studied to understand how truncation of the native hormone changes biological potency and half-life. It is a common research tool for mapping minimal active sequences within the GHRH family.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.